Radiation Therapy W/O Hippocampal Avoidance SCLC

RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER

  • Clinical Trial Information

    Trial Contact: Frankos, Marie; Manchola-Orozco, Carolina

    Trial Phone: 321.841.7303 ; 321.841.7293

  • IRB No: NRG-CC003

    Protocol Abbrev: NRG CC003

    Principal Investigator: Justin Mathew Rineer, MD

    Phase: Device: Category N/A

    Age Group: Adult

    Secondary Protocol No: NRG-CC003

    Treatment: Radiation: 3-Dimensional Conformal Radiation Therapy/ Intensity-Modulated Radiation Therapy

    Therapies Involved: Radiation

    ClinicalTrials.gov ID: NCT02635009

  • Objective

    This randomized phase II/III trial studies how well whole-brain radiation therapy works and compares it with or without hippocampal avoidance in treating patients with small cell lung cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only (limited stage) or has spread outside of the lung in which it began or to other parts of the body (extensive stage). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.

  • Key Eligibility

    Histologic proof or unequivocal cytologic proof (fine needle aspiration, biopsy or two positive sputa) of SCLC within 250 days prior to Step 1 registration.